U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.

Cover of StatPearls

StatPearls [Internet].

Show details

Transfusion Iron Overload

; ; .

Author Information and Affiliations

Last Update: February 12, 2024.

Continuing Education Activity

Patients with thalassemia, sickle cell disease, aplastic anemia, and myelodysplastic syndromes are often transfusion-dependent. Transfusion iron overload occurs as a result of numerous blood transfusions. Excess iron from multiple blood transfusions deposits in the heart, liver, pituitary, pancreas, and thyroid, causing organ damage and death. Proper screening techniques and chelation therapy prevent transfusion iron overload. This topic describes the etiology, pathophysiology, evaluation, and management of transfusion iron overload while highlighting the importance of the interprofessional team in caring for patients with this condition.

Objectives:

  • Identify the etiology of transfusion iron overload.
  • Implement appropriate monitoring and assessment protocols to track iron levels in patients at risk of transfusion iron overload.
  • Apply evidence-based guidelines and best practices for preventing and managing transfusion iron overload.
  • Collaborate with other healthcare professionals to ensure a comprehensive approach to diagnosing and managing transfusion iron overload.
Access free multiple choice questions on this topic.

Introduction

The human body is not able to excrete excess amounts of iron actively.[1] Iron is absorbed from the small intestine each day and balanced by losses through sweating, menstruation, shedding of hair and skin cells, and the rapid turnover and excretion of erythrocytes.[2] The average daily absorption and secretion is 1 mg. Patients receiving transfusions for non-iron deficiency anemias are at risk for transfusion-related iron overload. The following is a list of transfusion-dependent conditions:

  • Thalassemia major
  • Sickle cell disease
  • Myelodysplastic syndrome
  • Aplastic anemia
  • Hemolytic anemia
  • Refractory sideroblastic anemia

A unit of transfused blood contains approximately 200 to 250 mg of iron.[3] Some patients depend on multiple transfusions, and the excess iron deposits in the liver, endocrine organs, heart, and other tissues causing significant morbidity and mortality. Iron accumulates in and leaves different tissues at different rates. Iron chelation therapy is vital in preventing iron accumulation to morbid levels. The current understanding of iron hemostasis has dramatically increased the lifespan of patients who are transfusion-dependent. 

Liver disease is the most common complication. Patients who develop liver disease may progress to cirrhosis and face an increased risk of hepatocellular carcinoma. Iron cardiomyopathy is the leading cause of death in patients with thalassemia major. 

Serum ferritin, iron, and transferrin saturation levels in conjunction with cardiac T2* MRI and liver biopsy or MRI monitor the patient's iron status. Early iron-chelation therapy can prevent severe life-threatening consequences. 

Etiology

Transfusion-related iron overload correlates directly with a patient's number of blood transfusions. Conditions that necessitate repeated transfusions leading to invariable iron overload are:

  • β-thalassemia major
  • Myelodysplastic syndrome
  • Sickle cell disease
  • Aplastic anemia
  • Hemolytic anemia

One unit of transfused blood contains approximately 200 to 250 mg of iron.[3] Patients who undergo more than 10 to 20 units of blood transfusions face a substantial risk of developing iron overload.[3] No effective physiological mechanism for removing excess iron from the human body exists. For this reason, the body requires tight regulation of iron absorption and recycling. 

Hepcidin, a peptide hormone, regulates iron absorption by binding to ferroprotein, an iron exporter, on the surface of macrophages and enterocytes. Macrophages' daily phagocytosis of red blood cells accounts for approximately 25 mg of iron reclamation. This reclaimed iron is primarily in the ferrous (Fe2+) state, which is highly reactive and can cause damage to proteins and DNA. The ferrous iron state prompts ferritin production inside cells, where iron is sequestered and converted into the non-reactive ferric (Fe3+) state.

Fe3+ binds to transferrin. When the total body iron content surpasses the binding capacity of transferrin, the result is increased levels of the highly reactive ferrous iron in the body, or non-transferrin-bound iron (NTBI). This NTBI is also referred to as labile plasma iron (LPI). Non-transferrin-bound iron enters cells of the heart, liver, pancreas, and endocrine glands that transport other cations like calcium and zinc.[4] The heart, pancreas, and pituitary gland do not accumulate iron, except under pathological conditions.

Hepcidin regulates the release of iron from enterocytes and macrophages into the plasma. Elevated hepcidin levels impede the movement of iron absorbed by enterocytes and stored by macrophages into the bloodstream. Iron overload and inflammation can raise hepcidin levels. Conversely, hypoxia, anemia, and increased erythropoiesis reduce hepcidin, releasing Fe2+ into the plasma. Patients with ineffective erythropoiesis, such as those with thalassemia and aplastic anemia, tend to have higher iron levels than their transfusion-dependent counterparts.[5][6]

Epidemiology

In the United States, approximately 15,000 patients with sickle cell disease and 4500 patients with myelodysplastic syndromes and other causes of refractory anemias require regular blood transfusions. Internationally, the number reaches nearly 100,000.[7] The average age of transfusion onset is 4 and 12 for children with thalassemia and sickle cell disease, respectively. The average age for adults is 40 for aplastic anemia and 60 for patients with myelodysplastic syndromes.

The incidence of transfusion iron overload varies in different regions of the world, depending on the scope of early screening and preventive measures. One study reveals that delayed puberty is present in 51% of males and 47% of females with thalassemia. In another study of patients with thalassemia major, one-third were on regular chelation therapy, one-third on intermittent chelation therapy, and one-third on no chelation therapy; 85.64% had iron overload.

Patients in the West and the Far East have a higher iron burden in the myocardium compared to the Middle East.[8] A study in Japan reported that out of 1109 cases of iron overload, 93.1% occurred post-transfusion.[9] In a Greek cohort of transfusion-dependent patients with thalassemia major, 51% had moderate to severe iron overload with serum ferritin of more than 2000 mcg/L and more than 4000 mcg/L, respectively.[10]

Pathophysiology

The clinical manifestations of iron toxicity are silent for many years. The dynamics of iron regulation in the body are multifactorial and become aberrant in transfusion-induced iron overload. Chronic iron overload damages multiple organs, causing cardiomyopathy, liver cirrhosis, endocrinopathy, and arthritis.

The liver is the primary organ that stores iron, and ferritin and hemosiderin are the storage forms of iron. Hemosiderin is an insoluble form of iron storage comprised of trapped ferritin in lysosomal membranes. Hemosiderin does not circulate in blood like ferritin; instead, hemosiderin is deposited in tissues and remains unavailable when cells need iron.[11] When serum transferrin binding capacity is exceeded, LPI levels are high.

Labile plasma iron is highly reactive, toxic, or carcinogenic if present in excess. Labile plasma iron is a highly toxic component due to its high potential to generate oxygen-free radicals, damaging DNA, proteins, and membrane lipids. Ferritin serves as a protective mechanism against LPI. Iron overload occurs when LPI reacts with oxidants, making reactive oxygen species that rapidly degrade the proteins and DNA of a cell.[12] Over time, this leads to apoptosis of the target organ.[13] Recent studies suggest that reactive oxygen species levels also impair nitric oxide production and damage the vessel wall.[14]  

Increased intestinal iron absorption adds to iron overload in some disorders, including beta-thalassemia.[15] In thalassemia intermedia, the exaggerated activity of erythropoietin causes hepcidin deficiency, leading to excess absorption of dietary iron and iron overload. Contrary to this, in thalassemia major, the erythropoietic drive is low, and the iron load is high due to transfusions, leading to higher hepcidin levels. 

Histopathology

Conventional histological stains are incapable of identifying iron deposits within tissues. Therefore, special stains, like Prussian blue, are frequently employed to detect the presence of excess iron in tissues. When stained with Prussian blue, the appearance of a blue, granular pattern indicates iron deposition. In hepatocytes, iron deposition initiates in the periportal areas and progressively extends to involve centrilobular areas, Kupffer cells, and biliary epithelial cells. Over time, this iron deposition results in the development of fibrosis and micronodular cirrhosis. Likewise, we observe iron deposition and fibrosis in cardiac myocytes, the pancreas, endocrine glands, and the skin.[16]

History and Physical

To better assess the patient, clinicians should know how long they have been transfusion dependent, how many transfusions they receive per year, and their compliance with a chelation regimen. Most patients with transfusion iron overload typically suffer from fatigue, breathlessness, and pale skin, which are the underlying symptoms of anemia. The first presenting symptom is often delayed puberty. The remaining complaints vary based on the organ systems affected.[17]

General

  • Weight loss
  • Fatigue
  • Arthralgias
  • Pallor
  • Breathlessness

Cardiac

Cardiac symptoms are typically due to heart failure.

  • Orthopnea
  • Dyspnea
  • Lower extremity edema
  • Paroxysmal nocturnal dyspnea

Endocrine

Symptoms related to the endocrine system are due to iron deposition in the pancreas, thyroid, and pituitary gland.

  • Delayed puberty
  • Delayed menarche
  • Polyuria, polydipsia, polyphagia due to diabetes
  • Short stature

Gastrointestinal

Gastrointestinal symptoms are due to cirrhosis.

  • Abdominal pain and distension
  • Hematemesis
  • Melena
  • Cognitive deficits, sleep disturbance, bradykinesia, hyperreflexia, rigidity, myoclonus, and asterixis due to encephalopathy 

Physical examination findings vary according to the extent and duration of iron overload. Patients with transfusion iron overload may present with the following:[18]

  • Bronze or grey skin color
  • Bruising
  • Dwarfism
  • Cachexia
  • Delayed breast development in pubertal girls
  • Soft, small testes in males
  • Hepatomegaly
  • Ascites
  • Caput medusa
  • Jugular venous distension
  • Lower extremity edema
  • Pleural effusion

Evaluation

To date, no single lab test exists to mark iron overload. A serum ferritin level is an inexpensive and widely available way of assessing transfusion iron overload. A patient with thalassemia with a ferritin measurement >2500 ng/dL has an 80% greater chance of cardiac-related mortality.[19] However, an inflammatory disorder, malignancy, metabolic syndrome, renal failure, liver disease, and excessive alcohol intake can all lead to elevated ferritin levels making a single result an unreliable indicator of iron overload.[20][21] Most guidelines recommend obtaining serial serum ferritin and transferrin saturation levels every 3 months for a more accurate assessment of the body's iron level.[22] The ferritin level cutoff point for iron toxicity varies in the literature from 1000 ng/mL to 3000 ng/mL. Limitations of ferritin testing are the lack of specificity and interpatient variability. 

Serum iron levels are high in patients with iron overload, and the total iron-binding capacity (TIBC) is low. Serum and total body iron results depend on the method used.[19] Transferrin saturation is easy to measure but far from perfect. A transferrin saturation of over 50% indicates a high iron load. However, this is a dynamic number and could vary with inflammation. 

NTBI and LPI are specific markers for iron overload and may be valuable in monitoring clinical response to chelation therapy. Further studies and standardization of assays are necessary before the routine use of NTBI and LPI levels.

MRI is the gold standard for long-term liver and cardiac iron level monitoring. Cardiac T2* MRI has a better prognostic value in predicting cardiac risk.[23] T2*, measured in milliseconds, is the time required for the organ to lose approximately two-thirds of its signal. A reciprocal relationship exists between T2* and iron concentration as it shortens as iron concentration increases. A T2* <20 ms indicates an increased likelihood of impaired left ventricular ejection fraction (LVEF). Most guidelines recommend a cardiac and liver MRI once a year. If the liver iron concentration (LIC) is more than 0.15 mg/g dry weight (DW) or cardiac dysfunction is present, repeat the MRI every 6 months. If the LIC is normal, repeat the MRI every 2 years. Calculate the LIC using atomic absorption spectrophotometry on tissue obtained from the liver biopsy. MRI of the pancreas is not a good predictor of iron deposition in the pancreas.

The severity classifications of iron overload in the liver are:[24]

  • Mild < 7 mg/g dry weight
  • Moderate 7 to 15 mg/g dry weight
  • Severe >15 mg/g dry weight

A liver biopsy is the standard of care when MRI is not available. However, patient compliance and risk of bleeding have limited its use. Hepatic iron stores are an indicator of total body iron stores. Additional necessary testing is:

  • Free thyroxine (T4);
  • Thyroid-stimulating hormone (TSH);
  • Calcium;
  • Phosphate;
  • 25-OH vitamin D;
  • Fasting blood sugar;
  • Hemoglobin A1c;
  • Alanine aminotransferase and aspartate aminotransferase;
  • Echocardiography; and 
  • Bone density testing.[22]

Treatment / Management

Vitamin C enhances iron absorption from food. Patients should avoid vitamin C, alcohol, and iron supplements. Iron chelation therapy is the standard of care to prevent and reverse iron overload. Ideally, prophylactic iron chelation therapy begins before clinically significant iron overload occurs. 

Non-transferrin-bound iron and iron deposited in the liver are the most susceptible to chelation. When to begin chelation therapy depends on when the patient became transfusion dependent and the current damage. The current standard is to begin chelation therapy after 1 to 2 years of consistent or 15 to 20 transfusions. Patients with serum ferritin levels that exceed 1000 to 1500 mcg/L, liver iron levels >3 to 5 mg/g dry weight, or a cardiac T2* of less than 20 ms also warrant chelation therapy. These values correspond to approximately 120 to 200 mL of transfused RBCs/kg. The American Academy of Pediatrics recommends a serum ferritin level < 1500 ng/mL or liver iron < 7 mg/g dry weight for children. The success of therapy significantly depends on patient adherence. Therefore, the treatment regimen should be adjusted to improve patient compliance.

Commonly used chelators in the United States are deferoxamine (DFO), deferiprone, and deferasirox. Before initiating or altering iron chelation therapy, assess patients' iron loading and previous chelation rates.

Deferoxamine, administered as a continuous intravenous or subcutaneous infusion, is the treatment of choice for transfusion iron overload. Deferoxamine helps prevent diabetes, cardiac disease, and cirrhosis. In the body, deferoxamine chelates circulating and tissue iron and eliminates it in urine and bile.

In contrast, deferasirox is an orally active iron chelator that eliminates chelated iron in bile.[25] Once daily dosing and cost make deferasirox more appealing to patients. However, the potential adverse effects of gastrointestinal bleeding, agranulocytosis, neutropenia, thrombocytopenia, hepatic fibrosis, and kidney failure may limit its use. 

Both deferoxamine and deferasirox monotherapy significantly reduce cardiac and hepatic siderosis.[25][26] An average deferoxamine dose of 51 mg/kg at least five days weekly reduces the LIC level by 6.4 mg/g DW.[27] An average deferasirox dose of 30 mg/kg daily reduces the LIC level by 3.1 to 7.8 mg/g DW.[28] The dose of iron-chelating agents is frequently titrated based on serum ferritin, liver, and cardiac imaging. The goal is to keep the serum ferritin level under 1000 mcg/L, the cardiac T2* over 20 ms, and the LIC less than 3 mg/g DW.[29][30][31] In young children, the dose of deferoxamine should not exceed 25 to 30 mg/kg to minimize adverse effects. Pregnant or breastfeeding patients should avoid chelation therapy.[7] 

Maintenance Therapy

Maintenance therapy prevents tissue damage from iron overload.[32] A LIC of more than 15 mg/g dry weight, serum ferritin >2500 μg/L, or cardiac T2* MRI <20 ms indicates inadequate chelation. If there is cardiac iron overload, cardiac iron chelation becomes the primary goal of therapy. Not all patients achieve adequate chelation on one iron chelator. Many patients will need their treatment revised, sometimes needing a higher dose, a different chelator, or a combination of chelators. If transfusional requirements are exceptionally high, more than 200 to 220 mL packed red cells/kg/year, splenectomy can reduce the iron uptake from transfusions. Liver and heart transplantation are considerations for patients who have end-stage disease. 

Differential Diagnosis

Medical conditions that mimic transfusion iron overload are:

  • Hemochromatosis;
  • Cardiomyopathy;
  • Acute inflammatory conditions;
  • Malignancy;
  • Arthritis;
  • Diabetes;
  • Hepatitis C;
  • Human immunodeficiency virus (HIV) infection; and
  • Dysmetabolic hyperferritinemia.[33]

Pertinent Studies and Ongoing Trials

Several novel concepts that may help effectively treat iron overload and the patient's overall survival are under investigation. A randomized controlled trial on amlodipine, a calcium channel blocker as an adjuvant iron chelator, shows a significant decrease in myocardial iron concentration.[34] Several phase 2 studies have shown improved adherence with a film-coated oral tablet of deferasirox compared to a dispersible tablet.[35] Gene therapy is another promising option to reduce the transfusion requirement by improving endogenous erythropoiesis.[36] A janus kinase (JAK2) inhibitor and hepcidin analog are additional investigational therapies.[37][38]

Prognosis

Without chelation therapy, the likelihood of death due to arrhythmia or heart failure is high in late childhood or early adolescence. The prognosis of individuals with iron overload depends heavily on early detection and adherence to preventive measures. Cardiac toxicity and endocrine toxicity are reversible, but the outcomes may vary. Since the introduction of preventive iron chelating therapy (ICT), there has been a consistent improvement in the quality of life and survival of individuals with transfusion iron overload.[39] These individuals continue to face an elevated risk of developing malignancies, and their overall mortality rate is three times higher than that of the general population.[40]

Complications

Without chelation therapy, the likelihood of death due to arrhythmia or heart failure is high in late childhood or early adolescence. The prognosis of individuals with iron overload depends heavily on early detection and adherence to preventive measures. Cardiac toxicity and endocrine toxicity are reversible, but the outcomes may vary. Since the introduction of preventive iron chelating therapy (ICT), there has been a consistent improvement in the quality of life and survival of individuals with transfusion iron overload. These individuals continue to face an elevated risk of developing malignancies, and their overall mortality rate is three times higher than that of the general population.

Complications of Transfusion Iron Overload

Long-term complications of transfusion iron overload are:

  • Liver cirrhosis
  • hepatic failure
  • cardiomyopathy
  • cardiac conduction defects
  • heart failure
  • diabetes
  • hypogonadism
  • malignancy
  • hypoparathyroidism
  • adrenal insufficiency and need for stress dose steroids
  • hypothyroidism; and
  • arthropathy.[40] 

Dilated cardiomyopathy is the most common cause of early death.

Complications of Chelation Therapy

Deferoxamine

  • Retinal damage causing night blindness, visual field loss, and retinal pigmentation
  • High-tone sensorineural hearing loss
  • Growth and bone defects in children causing rickets-like bone lesions, metaphyseal changes, and spinal damage
  • Calculate a therapeutic index as the mean daily dose (mg/kg)/current serum ferritin (μg/L). If this is < 0.025 at all times, these side effects of DFO do not occur.

Children should be monitored for visual and auditory deficits every 6 months, and adults every 12 months. Monitor children's growth regularly. Sitting height compared to total height can help signify early spinal growth defects.[41][42][43][44][45]

Deferasirox

  • Nausea, vomiting, and diarrhea
  • Elevated liver transaminases
  • Acute kidney injury
  • Auditory and visual changes

Establish baseline renal function. Check renal function monthly or weekly for the first month if the patient has additional renal risk factors. Adjust the dose accordingly based on renal function.[46][47][46] 

 Deferiprone 

  • Agranulocytosis
  • Elevated liver transaminases
  • Arthropathy
  • Zinc deficiency

Monitor CBC weekly for the first year and every 2 weeks subsequently. Discontinue therapy if transaminases more than twice normal consistently. Give zinc supplements. 

Deterrence and Patient Education

Patients with illnesses like thalassemia, aplastic anemia, sickle cell disease, and myelodysplastic syndrome are often transfusion-dependent. Each time the body receives a blood transfusion, it receives approximately 200 to 250 mg of extra iron. The human body has no physiological process to eliminate extra iron. After multiple blood transfusions, the excess iron accumulates in the liver, heart, pancreas, pituitary, and thyroid. This accumulation will lead to liver cirrhosis, cardiomyopathy, heart failure, hypothyroidism, hypogonadism, diabetes, and delayed puberty.

Iron chelation therapy involves medication given intravenously, subcutaneously, or orally that will bind and eliminate extra iron in the body. Chelation therapy helps prevent cirrhosis, damage to the heart, and diabetes. Healthcare professionals will monitor the body's total iron stores with serial blood tests. The current recommendations are to monitor serum ferritin levels every 3 months and a serum iron panel annually. An annual MRI, or biopsy of the liver if MRI is unavailable, monitors the iron content in those organs. Obtain an MRI every 3 to 6 months for patients with heart failure and intensive chelation therapy.[19] Blood glucose, vitamin D, calcium, and thyroid levels are also monitored. 

Chelation therapy is vital to improving long-term survival. Discussion with the patient and family about the advantages and disadvantages of chelation therapy is vital to improve the patient's compliance.[7] Patients will be closely monitored to prevent adverse outcomes from the chelation medications. Patients should avoid iron-rich foods like red meat, beans, spinach, and excess vitamin C. 

Enhancing Healthcare Team Outcomes

Patients who are transfusion-dependent face many challenges. They suffer from the symptoms of chronic anemia, can spend much time receiving transfusions and chelation therapy, experience significant medical costs, and face potential early mortality. Communication among interprofessional healthcare team members, including primary care, hematology, psychiatry, psychology, nursing, cardiology, gastroenterology, endocrinology, ophthalmology, audiology, and other healthcare staff, is essential to prevent, diagnose, and manage transfusion iron overload.

Adherence to follow-up and iron-chelation therapy has improved morbidity and mortality overall.[48] Transfusion iron overload has a multiorgan impact. A supportive interprofessional team aware of the underlying risks, complications of recurrent transfusions, and potential adverse effects of chelation therapy is essential in providing comprehensive care. Each team member must ensure the patient is adequately screened and treated within their designated specialty, distribute up-to-date treatment information to the rest of the team, and check that the patient has care scheduled with the additional members. The psychological effect of long-term transfusion therapy is common, and early evaluation of depression, anxiety, and other disorders is essential. Consideration of the financial implications for long-term treatment is also important. A patient-centered team approach will reduce overall morbidity and mortality.

Review Questions

References

1.
Anderson GJ. Mechanisms of iron loading and toxicity. Am J Hematol. 2007 Dec;82(12 Suppl):1128-31. [PubMed: 17963252]
2.
Munro MG, Mast AE, Powers JM, Kouides PA, O'Brien SH, Richards T, Lavin M, Levy BS. The relationship between heavy menstrual bleeding, iron deficiency, and iron deficiency anemia. Am J Obstet Gynecol. 2023 Jul;229(1):1-9. [PubMed: 36706856]
3.
Woei-A-Jin FJSH, Zheng SZ, Kiliçsoy I, Hudig F, Luelmo SAC, Kroep JR, Lamb HJ, Osanto S. Lifetime Transfusion Burden and Transfusion-Related Iron Overload in Adult Survivors of Solid Malignancies. Oncologist. 2020 Feb;25(2):e341-e350. [PMC free article: PMC7011667] [PubMed: 32043782]
4.
Coates TD. Physiology and pathophysiology of iron in hemoglobin-associated diseases. Free Radic Biol Med. 2014 Jul;72:23-40. [PMC free article: PMC4940047] [PubMed: 24726864]
5.
Pietrangelo A. Hereditary hemochromatosis. Biochim Biophys Acta. 2006 Jul;1763(7):700-10. [PubMed: 16891003]
6.
Anderson GJ, Darshan D, Wilkins SJ, Frazer DM. Regulation of systemic iron homeostasis: how the body responds to changes in iron demand. Biometals. 2007 Jun;20(3-4):665-74. [PubMed: 17273818]
7.
Brittenham GM. Iron-chelating therapy for transfusional iron overload. N Engl J Med. 2011 Jan 13;364(2):146-56. [PMC free article: PMC3078566] [PubMed: 21226580]
8.
Aydinok Y, Porter JB, Piga A, Elalfy M, El-Beshlawy A, Kilinç Y, Viprakasit V, Yesilipek A, Habr D, Quebe-Fehling E, Pennell DJ. Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study. Eur J Haematol. 2015 Sep;95(3):244-53. [PubMed: 25418187]
9.
Ikuta K, Hatayama M, Addo L, Toki Y, Sasaki K, Tatsumi Y, Hattori A, Kato A, Kato K, Hayashi H, Suzuki T, Kobune M, Tsutsui M, Gotoh A, Aota Y, Matsuura M, Hamada Y, Tokuda T, Komatsu N, Kohgo Y. Iron overload patients with unknown etiology from national survey in Japan. Int J Hematol. 2017 Mar;105(3):353-360. [PubMed: 27848180]
10.
Ladis V, Chouliaras G, Berdousi H, Kanavakis E, Kattamis C. Longitudinal study of survival and causes of death in patients with thalassemia major in Greece. Ann N Y Acad Sci. 2005;1054:445-50. [PubMed: 16339695]
11.
Saito H. Storage Iron Turnover from a New Perspective. Acta Haematol. 2019;141(4):201-208. [PubMed: 30943466]
12.
Coates TD. Iron overload in transfusion-dependent patients. Hematology Am Soc Hematol Educ Program. 2019 Dec 06;2019(1):337-344. [PMC free article: PMC6913424] [PubMed: 31808901]
13.
Gordan R, Wongjaikam S, Gwathmey JK, Chattipakorn N, Chattipakorn SC, Xie LH. Involvement of cytosolic and mitochondrial iron in iron overload cardiomyopathy: an update. Heart Fail Rev. 2018 Sep;23(5):801-816. [PMC free article: PMC6093778] [PubMed: 29675595]
14.
Marques VB, Nascimento TB, Ribeiro RF, Broseghini-Filho GB, Rossi EM, Graceli JB, dos Santos L. Chronic iron overload in rats increases vascular reactivity by increasing oxidative stress and reducing nitric oxide bioavailability. Life Sci. 2015 Dec 15;143:89-97. [PubMed: 26523985]
15.
Lal A. Iron in Health and Disease: An Update. Indian J Pediatr. 2020 Jan;87(1):58-65. [PubMed: 31520313]
16.
Deugnier Y, Turlin B. Pathology of hepatic iron overload. World J Gastroenterol. 2007 Sep 21;13(35):4755-60. [PMC free article: PMC4611197] [PubMed: 17729397]
17.
Gupta V, Aggarwal P. Complications in Transfusion-Dependent Thalassemia. Indian Pediatr. 2022 Dec 15;59(12):911-912. [PubMed: 36511205]
18.
Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, Laouri M. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010 Jun 10;28(17):2847-52. [PubMed: 20421543]
19.
Wood JC. Diagnosis and management of transfusion iron overload: the role of imaging. Am J Hematol. 2007 Dec;82(12 Suppl):1132-5. [PMC free article: PMC2892928] [PubMed: 17963249]
20.
Cullis JO, Fitzsimons EJ, Griffiths WJ, Tsochatzis E, Thomas DW., British Society for Haematology. Investigation and management of a raised serum ferritin. Br J Haematol. 2018 May;181(3):331-340. [PubMed: 29672840]
21.
Koperdanova M, Cullis JO. Interpreting raised serum ferritin levels. BMJ. 2015 Aug 03;351:h3692. [PubMed: 26239322]
22.
Taher AT, Saliba AN. Iron overload in thalassemia: different organs at different rates. Hematology Am Soc Hematol Educ Program. 2017 Dec 08;2017(1):265-271. [PMC free article: PMC6142532] [PubMed: 29222265]
23.
Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001 Dec;22(23):2171-9. [PubMed: 11913479]
24.
Telfer PT, Prestcott E, Holden S, Walker M, Hoffbrand AV, Wonke B. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol. 2000 Sep;110(4):971-7. [PubMed: 11054091]
25.
Pennell DJ, Porter JB, Cappellini MD, El-Beshlawy A, Chan LL, Aydinok Y, Elalfy MS, Sutcharitchan P, Li CK, Ibrahim H, Viprakasit V, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood. 2010 Mar 25;115(12):2364-71. [PubMed: 19996412]
26.
Aydinok Y, Ulger Z, Nart D, Terzi A, Cetiner N, Ellis G, Zimmermann A, Manz C. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major. Haematologica. 2007 Dec;92(12):1599-606. [PubMed: 18055982]
27.
Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa M, Giardina P, Kourakli-Symeonidis A, Janka-Schaub G, Coates T, Vermylen C, Olivieri N, Thuret I, Opitz H, Ressayre-Djaffer C, Marks P, Alberti D. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006 May 01;107(9):3455-62. [PubMed: 16352812]
28.
Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, Drelichman G, Economou M, Fattoum S, Kattamis A, Kilinc Y, Perrotta S, Piga A, Porter JB, Griffel L, Dong V, Clark J, Aydinok Y. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood. 2011 Jul 28;118(4):884-93. [PubMed: 21628399]
29.
Aydinok Y, Kattamis A, Viprakasit V. Current approach to iron chelation in children. Br J Haematol. 2014 Jun;165(6):745-55. [PubMed: 24646011]
30.
Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997 Feb 01;89(3):739-61. [PubMed: 9028304]
31.
Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood. 2011 Sep 29;118(13):3479-88. [PubMed: 21813448]
32.
Inati A, Khoriaty E, Musallam KM, Taher AT. Iron chelation therapy for patients with sickle cell disease and iron overload. Am J Hematol. 2010 Oct;85(10):782-6. [PubMed: 20721892]
33.
Mendler MH, Turlin B, Moirand R, Jouanolle AM, Sapey T, Guyader D, Le Gall JY, Brissot P, David V, Deugnier Y. Insulin resistance-associated hepatic iron overload. Gastroenterology. 1999 Nov;117(5):1155-63. [PubMed: 10535879]
34.
Khaled A, Salem HA, Ezzat DA, Seif HM, Rabee H. A randomized controlled trial evaluating the effects of amlodipine on myocardial iron deposition in pediatric patients with thalassemia major. Drug Des Devel Ther. 2019;13:2427-2436. [PMC free article: PMC6659783] [PubMed: 31413542]
35.
Taher AT, Origa R, Perrotta S, Kourakli A, Ruffo GB, Kattamis A, Goh AS, Cortoos A, Huang V, Weill M, Merino Herranz R, Porter JB. New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study. Am J Hematol. 2017 May;92(5):420-428. [PMC free article: PMC6585741] [PubMed: 28142202]
36.
Cavazzana M, Antoniani C, Miccio A. Gene Therapy for β-Hemoglobinopathies. Mol Ther. 2017 May 03;25(5):1142-1154. [PMC free article: PMC5417842] [PubMed: 28377044]
37.
Motta I, Scaramellini N, Cappellini MD. Investigational drugs in phase I and phase II clinical trials for thalassemia. Expert Opin Investig Drugs. 2017 Jul;26(7):793-802. [PubMed: 28540737]
38.
Preza GC, Ruchala P, Pinon R, Ramos E, Qiao B, Peralta MA, Sharma S, Waring A, Ganz T, Nemeth E. Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. J Clin Invest. 2011 Dec;121(12):4880-8. [PMC free article: PMC3225996] [PubMed: 22045566]
39.
Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95(1):26-36. [PubMed: 8604584]
40.
Fung EB, Harmatz P, Milet M, Ballas SK, De Castro L, Hagar W, Owen W, Olivieri N, Smith-Whitley K, Darbari D, Wang W, Vichinsky E., Multi-Center Study of Iron Overload Research Group. Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload. Am J Hematol. 2007 Apr;82(4):255-65. [PubMed: 17094096]
41.
Olivieri NF, Buncic JR, Chew E, Gallant T, Harrison RV, Keenan N, Logan W, Mitchell D, Ricci G, Skarf B. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med. 1986 Apr 03;314(14):869-73. [PubMed: 3485251]
42.
De Sanctis V, Roos M, Gasser T, Fortini M, Raiola G, Galati MC., Italian Working Group on Endocrine Complications in Non-Endocrine Diseases. Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia. J Pediatr Endocrinol Metab. 2006 Apr;19(4):471-80. [PubMed: 16759032]
43.
Chan YL, Pang LM, Chik KW, Cheng JC, Li CK. Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia. Pediatr Radiol. 2002 Jul;32(7):492-7. [PubMed: 12107582]
44.
Robins-Browne RM, Prpic JK. Effects of iron and desferrioxamine on infections with Yersinia enterocolitica. Infect Immun. 1985 Mar;47(3):774-9. [PMC free article: PMC261386] [PubMed: 3972453]
45.
Ammon A, Rumpf KW, Hommerich CP, Behrens-Baumann W, Rüchel R. [Rhinocerebral mucormycosis during deferoxamine therapy]. Dtsch Med Wochenschr. 1992 Sep 18;117(38):1434-8. [PubMed: 1526205]
46.
Wu SF, Peng CT, Wu KH, Tsai CH. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients. Hemoglobin. 2006;30(2):215-8. [PubMed: 16798646]
47.
Tricta F, Uetrecht J, Galanello R, Connelly J, Rozova A, Spino M, Palmblad J. Deferiprone-induced agranulocytosis: 20 years of clinical observations. Am J Hematol. 2016 Oct;91(10):1026-31. [PMC free article: PMC5129477] [PubMed: 27415835]
48.
Ricchi P, Meloni A, Pistoia L, Spasiano A, Spiga A, Allò M, Gamberini MR, Lisi R, Campisi S, Peluso A, Missere M, Renne S, Mangione M, Positano V, Pepe A. The effect of desferrioxamine chelation versus no therapy in patients with non transfusion-dependent thalassaemia: a multicenter prospective comparison from the MIOT network. Ann Hematol. 2018 Oct;97(10):1925-1932. [PubMed: 29926157]

Disclosure: Mohammad Rasel declares no relevant financial relationships with ineligible companies.

Disclosure: Muhammad Hashmi declares no relevant financial relationships with ineligible companies.

Disclosure: Sohail Mahboobi declares no relevant financial relationships with ineligible companies.

Copyright © 2024, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.

Bookshelf ID: NBK562146PMID: 32965817

Views

  • PubReader
  • Print View
  • Cite this Page

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...